

Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: [doi:10.31222/osf.io/9sm4x](https://doi.org/10.31222/osf.io/9sm4x)). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		N/A. This does not apply to our study
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		N/A. This does not apply to our study
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		N/A. This does not apply to our study
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID		N/A. This does not apply to our study
Animal observed in or captured from the field: Provide species, sex and age where possible		N/A. This does not apply to our study
Model organisms: Provide Accession number in repository (where relevant) OR RRID		N/A. This does not apply to our study
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		N/A. This does not apply to our study
Microbes: provide species and strain, unique accession number if available, and source		N/A. This does not apply to our study
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		N/A. This does not apply to our study. We used publicly available patient cohorts.
Provide statement confirming informed consent obtained from study participants.		N/A. This does not apply to our study
Report on age and sex for all study participants.		N/A. This does not apply to our study

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.		N/A. This does not apply to our study
Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		N/A. This does not apply to our study
Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been done, or if they were not carried out.		
Sample size determination		
Randomisation		N/A. This does not apply to our study
Blinding		N/A. This does not apply to our study
Inclusion/exclusion criteria		
Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory		N/A. This does not apply to our study
Define whether data describe technical or biological replicates		N/A. This does not apply to our study
Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		N/A. This does not apply to our study. We used publicly available patient cohorts from the TCGA.
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		N/A. This does not apply to our study
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		N/A. This does not apply to our study
Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		N/A. This does not apply to our study

Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		N/A. This does not apply to our study. We used publicly available patient cohorts
Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	Page 7; line 145-149	
Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		N/A. This does not apply to our study.
If data are publicly available, provide accession number in repository or DOI or URL.		
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Page 5; line 110-120 and 124-135	N/A. This does not apply to our study.
Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential for replicating the main findings of the study:		N/A. This does not apply to our study.
State whether the code or software is available.		N/A. This does not apply to
If code is publicly available, provide accession number in repository, or DOI or URL.		N/A. This does not apply to our study.

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	Page 17; line 374-375 ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: <http://dx.doi.org/10.21037/gs-20-571>.